Rocket Lab Price Targets Are Falling, but We’re Making Another Trade Today
Our repair work continues on the $10,000 Portfolio.
You've reached your free article limit
You've read 0 of 1 free Pro articles.
On Thursday, after my unexpected but necessary and lengthy time away from actively managing the $10,000 Portfolio and the portfolio’s poor recent performance, we took several steps to try to stabilize the book without running cash levels down to nothing. Remember, we do not use margin here to initiate or increase exposure to long positions, so we are often put in the position of robbing Peter to pay Paul.
We also publish just once a day and must act after the information provided is public, so there are several restrictions. That said, the performance has been undeniably ugly.
This morning, readers will note that there has been a ton of analyst activity in names that are currently part of this book. Take a good look at the professional coverage of Rocket Lab (RKLB). A lot of price target reductions there. We were already below $100 on our target and may have to cut that number again soon.
Friday’s Intention
– Purchase 20 shares of ONDS at or close to the last sale of $6.31.
Thursday’s Intentions vs Actual Trades
– Sell 50 shares of VELO at or close to the last sale of $6.75 to close the position.
– Sold 50 shares of VELO at $7.12.
– Sell 60 shares of EVLV at or close to the last sale of $4.09 to leave 50 shares.
– Sold 60 shares of EVLV at $4.145.
– Purchase 10 shares of OCUL at or close to the last sale of $7.20.
– Bought 10 shares of OCUL at $7.339.
– Purchase 20 shares of SOFI at or close to the last sale of $13.93.
– Bought 20 shares of SOFI at $14.935.
– Purchase 3 shares of RKLB at or close to the last sale of $52.77.
– Bought 3 shares of RKLB at $54.61.
– Purchase 20 shares of ONDS at or close to the last sale of $5.92.
– Bought 20 shares of ONDS at $6.283.
Analyst Activity
Ocular Therapeutix
Earlier this week, analyst Tazeen Ahmad of Bank of America reiterated her “buy” rating as well as her $27 price target on Ocular Therapeutix (OCUL). Ahmed is rated at 2.5 stars out of five by TipRanks. She has compiled a 47% success rate over the past two years while generating an average return of 0.6%.
Earlier this week, analyst Biren Amin of Piper Sandler reiterated his “buy” rating as well as his $14 price target on OCUL. Biren is rated at three stars out of five by TipRanks. He has compiled a 39% success rate over the past two years while generating an average return of 0.9%.
Ondas Inc.
Earlier this week, analyst Amit Dayal of H.C. Wainwright reiterated his “buy” rating as well as his $25 price target on Ondas (ONDS). Dayal is rated at three stars out of five by TipRanks. He has compiled a 28% success rate over the past two years while generating an average return of 1.3%.
Planet Labs
Early Friday morning, analyst Kristine Liwag of Morgan Stanley reiterated her “hold” rating on Planet Labs (PL) while cutting her price target to $19 from $35. Liwag is rated at five stars out of five by TipRanks. She has compiled a 56% success rate over the past two years while generating an average return of 11%.
Earlier this week, analyst Noah Poponak of Goldman Sachs reiterated his “hold” rating on PL while cutting his price target to $22 from $24. Poponak is rated at four stars out of five by TipRanks. He has compiled a 49% success rate over the past two years while generating an average return of 4.8%.
Peloton Interactive
Earlier this week, analyst Aneesha Sherman of Bernstein reiterated her “buy” rating as well as her $6 price target on Peloton (PTON). Sherman is rated at two stars out of five by TipRanks. She has compiled a 41% success rate over the past two years while generating an average return of 0.6%.
Earlier this week, analyst Arpine Kocharyan of UBS reiterated her “buy” rating on PTON without setting a price target. Kocharyan is rated at one star out of five by TipRanks. She has compiled a 46% success rate over the past two years while generating an average return of -3%.
Rocket Lab
On Thursday, analyst Suji Desilva of Roth MKM reiterated his “buy” rating as well as his $110 price target on Rocket Lab (RKLB). Desilva is rated at five stars out of five by TipRanks. He has compiled a 47% success rate over the past two years while generating an average return of 44.2%.
On Thursday, analyst Erik Rasmussen of Stifel Nicolaus reiterated his “buy” rating as well as his $132 price target on RKLB. Rasmussen is rated at five stars out of five by TipRanks. He has compiled a 66% success rate over the past two years while generating an average return of 33.7%.
On Thursday, analyst Michael LeShock of KeyBanc reiterated his “buy” rating on RKLB while cutting his price target to $100 from $135. LeShock is rated at five stars out of five by TipRanks. He has compiled a 49% success rate over the past two years while generating an average return of 35.5%.
On Thursday, analyst Noah Poponak of Goldman Sachs reiterated his “hold” rating on RKLB while cutting his price target to $67 from $75. Poponak is rated at four stars out of five by TipRanks. He has compiled a 49% success rate over the past two years while generating an average return of 4.8%.
On Thursday, analyst Andres Sheppard of Cantor Fitzgerald reiterated his “buy” rating as well as his $122 price target on RKLB. Sheppard is rated at three stars out of five by TipRanks. He has compiled a 37% success rate over the past two years while generating an average return of 2%.
On Thursday, analyst Gregory Pendy of Clear Street reiterated his “buy” rating on RKLB while cutting his price target to $95 from $129. Pendy is rated at 0.5 star out of five by TipRanks. He has compiled a 33% success rate over the past two years while generating an average return of -11.2%.
On Friday morning, analyst Trevor J. Walsh of Citizens JMP reiterated his “buy” rating on RKLB while cutting his price target to $90 from $130. Walsh is rated at five stars out of five by TipRanks. He has compiled a 66% success rate over the past two years while generating an average return of 30.6%.
On Friday morning, analyst Ryan Koontz of Needham reiterated his “buy” rating as well as his $120 price target on RKLB. Koontz is rated at five stars out of five by TipRanks. He has compiled a 44% success rate over the past two years while generating an average return of 25.7%.
SoFi Technologies
Earlier this week, analyst Will Nance of Goldman Sachs reiterated his “hold” rating on SOFI while cutting his price target to $15 from $18. Nance is rated at zero stars out of five by TipRanks. He has compiled a 45% success rate over the past two years while generating an average return of -6.4%.
On Friday morning, analyst David Konrad of KBW reiterated his “sell” rating as well as his $15 price target on SOFI. Konrad is rated at five stars out of five by TipRanks. He has compiled a 76% success rate over the past two years while generating an average return of 24.4%.
Current Positions
Long 60 shares of ASPN at $5.1083. Target Price: $10. Last sale: $5.39.
Long 50 shares of EVLV at $5.33.92. Target Price: $8.50. Last sale: $4.18.
Long 150 shares of OCUL at $8.3764. Target Price: $14. Last sale: $7.37.
Short one OCUL $9 Dec 18th call at $0.80, Last sale: $0.55.
Long 280 shares of ONDS at $7.9462. Target Price: $12. Last sale: $6.31.
Long 100 shares of PL at $20.3367. Target Price: $26. Last sale: $14.41.
Short one PL $17 Nov 19th call at $1.70, Last sale: $0.50.
Long 60 shares of PTON at $5.0263. Target Price: $9. Last sale: $5.28.
Long 8 shares of RKLB at $65.99. Target Price $97. Last sale: $54.94.
Long 150 shares of SOFI at $15.90. Target Price: $24. Last sale: $15.05.
Cash: $843.42.
Portfolio Value: $8,630.72, -13.7% from inception on March 24th.
At the time of publication, Guilfoyle was long ASPN, EVLV, OCUL, ONDS, PL, PTON, RKLB and SOFI
